Core Viewpoint - China National Pharmaceutical Group (01177) experienced a 3.28% increase in stock price, reaching 7.87 CNY per share with a transaction volume of 300 million CNY as of 10:21 AM on August 15 [1] Group 1: Company Overview - China National Pharmaceutical Group is an innovative research and development-driven pharmaceutical company, focusing on drug research, intelligent manufacturing, and sales [1] - The company specializes in various biological and chemical drugs, particularly excelling in four therapeutic areas: oncology, liver disease, respiratory system, and surgical/pain management [1] - Since its listing in 2000, the company has been included in multiple indices such as the MSCI Global Standard Index and the Hang Seng Index, and has been recognized in the "Top 50 Global Pharmaceutical Companies" by Pharmaceutical Manager for six consecutive years [1] Group 2: Financial Performance - As of the 2024 annual report, the company reported total revenue of 28.866 billion CNY and a net profit of 3.5 billion CNY [1] - The revenue contribution from the company's products has been increasing year by year [1] - The company is set to disclose its mid-year report for the fiscal year 2025 on August 18 [1]

Core Viewpoint - China Biologic Products (01177) has received acceptance for the clinical trial application (IND) of its innovative drug TQB3142, a Bcl-xL PROTAC molecule, from the National Medical Products Administration (NMPA) in China, aimed at treating malignant tumors [1] Group 1: Product Details - TQB3142 targets the degradation of the Bcl-xL protein through the ubiquitin-proteasome system, which alleviates its inhibition on tumor cell apoptosis, thereby activating the Caspase cascade and inducing programmed cell death in tumor cells [1] - Research indicates that TQB3142 demonstrates significant anti-tumor activity in various transplant tumor models and has a lower risk of platelet toxicity compared to similar candidate drugs, offering a better therapeutic window with controllable metabolic risks [1] Group 2: Market Position - Currently, there are no approved Bcl-xL inhibitors available globally, making TQB3142 a novel mechanism anti-tumor drug [1] - The drug's molecular design optimization allows it to maintain degradation activity while reducing blood toxicity risks, potentially providing new treatment options for patients with malignant tumors [1]

Core Viewpoint - China Biopharmaceutical (01177.HK) has received acceptance for the clinical trial application (IND) of its innovative drug TQB3142, a Bcl-xL PROTAC molecule, from the National Medical Products Administration (NMPA) in China, aimed at treating malignant tumors [1] Group 1: Drug Mechanism and Efficacy - TQB3142 targets the degradation of the Bcl-xL protein through the ubiquitin-proteasome system, which alleviates its inhibition on tumor cell apoptosis, thereby activating the Caspase cascade and inducing programmed cell death in tumor cells [1] - The drug has shown significant anti-tumor activity in various transplantation tumor models and has a lower risk of platelet toxicity compared to similar candidate drugs, indicating a better therapeutic window and controllable metabolic risks [1] Group 2: Market Position and Potential - Currently, there are no approved Bcl-xL inhibitors available globally, making TQB3142 a novel mechanism anti-tumor drug [1] - The optimization of molecular design in TQB3142 allows for the maintenance of degradation activity while reducing blood toxicity risks, potentially providing new treatment options for patients with malignant tumors [1]

Core Viewpoint - China Biologic Products (01177) has received acceptance for the clinical trial application (IND) of its innovative drug TQB3142, a Bcl-xL PROTAC molecule, from the National Medical Products Administration (NMPA) in China, aimed at treating malignant tumors [1] Group 1: Drug Mechanism and Efficacy - TQB3142 targets the degradation of the Bcl-xL protein through the ubiquitin-proteasome system, which alleviates its inhibition on tumor cell apoptosis, thereby activating the Caspase cascade and inducing programmed cell death in tumor cells [1] - Research indicates that TQB3142 demonstrates significant anti-tumor activity across various transplant tumor models, with lower platelet toxicity risk compared to similar candidate drugs, offering a better therapeutic window and controllable metabolic risks [1] Group 2: Market Position and Potential - Currently, there are no approved Bcl-xL inhibitors globally, making TQB3142 a novel mechanism anti-tumor drug [1] - The drug's optimized molecular design maintains degradation activity while reducing blood toxicity risks, potentially providing new treatment options for patients with malignant tumors [1]

（於開曼群島註冊成立之有限公司） 網站：www.sinobiopharm.com （股份編號：1177） 自願公告 TQB3142「Bcl-xL PROTAC」臨床試驗申請獲NMPA受理 中國生物製藥有限公司（「本公司」，連同其附屬公司統稱「本集團」）董事會（「董事會」）宣佈，本集團自 主研發的創新藥TQB3142「Bcl-xL PROTAC （蛋白降解靶向嵌合體）」的新藥臨床試驗申請(IND)已獲 得中國國家藥品監督管理局(NMPA)受理，擬用於治療惡性腫瘤。 TQB3142是一款靶向降解Bcl-xL蛋白的PROTAC分子，通過泛素－蛋白酶體系統特異性降解Bcl-xL 蛋白，解除其對腫瘤細胞凋亡的抑制，從而激活Caspase級聯反應，誘導腫瘤細胞程序性死亡。研 究顯示，TQB3142在多種移植瘤模型中表現出顯著抑瘤活性，且對血小板毒性風險低於同類候選藥 物，具有更優的治療窗口，代謝風險可控。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 中國生物 ...

Core Viewpoint - China Biologic Products (01177) has received acceptance from the National Medical Products Administration (NMPA) for the clinical trial application of its innovative drug TQB3122, a PARP1 inhibitor intended for the treatment of advanced malignant tumors [1] Group 1: Product Details - TQB3122 is a highly selective PARP1 inhibitor with the ability to penetrate the blood-brain barrier, demonstrating anti-tumor effects through a dual mechanism [1] - The drug competitively inhibits the catalytic activity of the PARP1 enzyme, blocking DNA single-strand break repair, and stabilizes the DNA-PARP complex to hinder replication fork progression [1] - Based on the principle of "synthetic lethality," TQB3122 selectively targets tumor cells with BRCA mutations or homologous recombination deficiencies [1] Group 2: Clinical Potential - Research indicates that TQB3122 shows significant efficacy across multiple tumor models and has outstanding distribution capabilities in brain tissue, making it a potential new option for treating intracranial tumors [1] - Currently, there are no approved drugs targeting the same mechanism globally, positioning TQB3122 as a novel therapeutic choice for patients with advanced solid tumors [1]

Core Viewpoint - China Biopharmaceutical's innovative drug TQB3122, a PARP1 inhibitor, has received acceptance for clinical trial application from the National Medical Products Administration (NMPA) in China, aimed at treating advanced malignant tumors [1] Group 1: Drug Development - TQB3122 is characterized by high selectivity and the ability to penetrate the blood-brain barrier, providing a dual mechanism for anti-tumor action [1] - The drug works by competitively inhibiting the catalytic activity of the PARP1 enzyme, blocking DNA single-strand break repair, and stabilizing the DNA-PARP complex to hinder replication fork progression [1] - TQB3122 selectively targets and kills tumor cells with BRCA mutations or homologous recombination deficiencies based on the principle of "synthetic lethality" [1] Group 2: Clinical Potential - Research indicates that TQB3122 shows significant efficacy across multiple tumor models and has outstanding distribution capabilities in brain tissue, making it a potential new option for treating intracranial tumors [1] - Currently, there are no approved drugs targeting the same pathway globally, positioning TQB3122 as a unique therapeutic candidate [1] - The company aims to explore the safety and efficacy of TQB3122 in advanced solid tumors, potentially providing new treatment options for patients worldwide [1]

Core Viewpoint - China Biopharmaceutical (01177) has received acceptance for the clinical trial application (IND) of its innovative drug TQB3122, a PARP1 inhibitor, from the National Medical Products Administration (NMPA) in China, aimed at treating advanced malignant tumors [1] Group 1: Drug Development - TQB3122 is a highly selective PARP1 inhibitor with the ability to penetrate the blood-brain barrier, utilizing a dual mechanism to exert anti-tumor effects [1] - The drug competitively inhibits the catalytic activity of the PARP1 enzyme, blocking DNA single-strand break repair, and stabilizes the DNA-PARP complex to hinder replication fork progression [1] - TQB3122 selectively targets and kills tumor cells with BRCA mutations or homologous recombination deficiencies based on the principle of "synthetic lethality" [1] Group 2: Clinical Potential - Research indicates that TQB3122 shows significant efficacy across multiple tumor models and has outstanding distribution capabilities in brain tissue, making it a potential new option for treating intracranial tumors [1] - Currently, there are no approved drugs targeting the same pathway globally, positioning TQB3122 as a novel therapeutic choice for patients with advanced solid tumors [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 目前，全球尚無同靶點藥物獲批上市。本集團將探索TQB3122在晚期實體瘤中的安全性與療效，有 望為全球患者提供新的治療選擇。 承董事會命 中國生物製藥有限公司 主席 謝其潤 香港，二零二五年八月十一日 1 （於開曼群島註冊成立之有限公司） 網站：www.sinobiopharm.com （股份編號：1177） 自願公告 TQB3122「PARP1抑制劑」臨床試驗申請獲NMPA受理 中國生物製藥有限公司（「本公司」，連同其附屬公司統稱「本集團」）董事會（「董事會」）宣佈，本集團自 主研發的創新藥TQB3122「PARP1抑制劑」的新藥臨床試驗申請(IND)已獲得中國國家藥品監督管理局 (NMPA)受理，擬用於治療晚期惡性腫瘤。 TQB3122是一款具有高選擇性和血腦屏障穿透能力的PARP1抑制劑，通過雙重機制發揮抗腫瘤作 用：一方面，競爭性抑制PARP1酶的催化活性，阻斷DNA單鏈斷裂修復；另一方面，通過 ...

Core Viewpoint - China National Pharmaceutical Group's subsidiary, Chengdu Tianqing, has received approval for its biosimilar Adalimumab (Taibowei) in Algeria, providing affordable treatment options for patients with autoimmune diseases in Belt and Road Initiative countries [1][2] Group 1: Product Approval and Market Impact - The approval of Taibowei marks a significant step in meeting the growing demand for high-quality biosimilars in Algeria, a key market in North Africa [2] - Adalimumab is a critical drug for treating various autoimmune diseases, including rheumatoid arthritis and psoriasis [1] - The successful approval reflects the company's commitment to innovation and internationalization, aligning with the Belt and Road Initiative [2] Group 2: Regulatory and Quality Management - The development of biosimilars requires demonstrating high similarity in quality, safety, and efficacy to the reference drug, with China's regulatory framework evolving since 2015 [1] - As of 2024, over 20 biosimilars have been approved in China, with Taibowei being a successful example of this process [1] - The company has established large R&D and production bases in Jiangsu, with multiple production lines certified by EU cGMP and US FDA, emphasizing the importance of quality management [1] Group 3: Future Strategy and Collaboration - The company plans to deepen collaboration with local partners in Algeria to accelerate the commercialization of its products [2] - The firm aims to leverage its established technology platform and existing biosimilars to support further international expansion [2] - Future efforts will focus on innovation and meeting clinical needs in Belt and Road countries, contributing to the "Health Silk Road" initiative [2]